MedTech Archives - AsiaPEVC.com

AdipoLABs Opens New Regional Office, Signs Two MoUs With University of Cyberjaya to Advance Healthcare Innovation

AdipoLABs Co., Ltd. and Red & Blue Co., Ltd. from Korea, together with their Malaysian subsidiary, AdipoLABs Healthcare (M) Sdn Bhd, today officially opened the new AdipoLABs regional office for Asia-Pacific, marking a strategic expansion to strengthen its leadership in non- invasive healthcare and build a robust MedTech ecosystem in Malaysia and across ASEAN.

Picture 1: Top row from left: ⁠Adjunct Prof. Dr. Yoo Seung-Mo, CEO, Red & Blue Co. Ltd; ⁠Dr. Isaac Joseph, Director of AdipoLABs Healthcare (M) Sdn Bhd; and Tan Sri Dato’ Dr. R. Palan, Pro Chancellor, UoC
Second row From left: Adjunct Prof. Han Sung-ho, President & CEO, AdipoLABs Healthcare Korea; Mr. Moses Balagopal, Director, AdipoLABs Healthcare (M) Sdn Bhd and Professor Dr. David Whitford, Vice Chancellor, UoC

As a research and development-focused medical company, its presence is expected to drive knowledge transfer, foster R&D collaboration, provide industry-standard training, and enhance the country’s preventive healthcare capabilities. To commemorate this milestone, the company also signed two Memoranda of Understanding (MoUs) with the University of Cyberjaya (UoC), formalising a partnership to advance healthcare innovation, clinical research, and talent development.

“By uniting our hyperthermia technology with local expertise and academic rigour, we’ll expedite the adoption of advanced solutions and improve patient outcomes worldwide. We envision this collaboration as a blueprint for international healthcare partnerships,” said Mr. Han Sung-ho, CEO of AdipoLABs Co., Ltd.

Picture 2: Left to right – Adjunct Prof. Dr. Yoo Seung-Mo, CEO, Red & Blue Co. Ltd, Adjunct Prof. Han Sung-ho, President & CEO, AdipoLABs Healthcare Korea, Dr. Isaac Joseph, Director of AdipoLABs Healthcare (M) Sdn Bhd, Professor Dr. David Whitford, Vice-Chancellor, University of Cyberjaya, Mr. Moses Balagopal, Director, AdipoLABs Healthcare (M) Sdn Bhd, Tan Sri Dato’ Dr. R. Palan, Pro-Chancellor, University of Cyberjaya.

A cornerstone of the first MoU is a comprehensive internship programme with UoC’s Physiotherapy programmes under the Faculty of Health, offering six-month placements and potential job opportunities to give students invaluable real-world experience. Students from the Faculty of Health will gain hands-on expertise with AdipoLABs’ Pain Bot device, enhancing their skills in pain detection and treatment, while students from the School of Biomedical Engineering will support AdipoLABs’ technical operations, strengthening after-sales service and device maintenance.

As part of the partnership, AdipoLABs will implement a strategic client engagement initiative, where interns may be placed at client facilities to demonstrate device effectiveness and provide on-site support. This initiative highlights the interns’ value, encourages potential permanent employment, and ensures optimal use of the technology. The collaboration also extends to clinical research, with UoC professors and students conducting studies on various AdipoLABs medical devices, generating evidence-based insights to be published in reputable journals and scientifically validating the technologies.

“We’re thrilled to collaborate with the University of Cyberjaya to cultivate local talent and drive Malaysian healthcare innovation. This partnership offers UoC students invaluable hands-on experience with technologies like Pain Bot. It also expands our clinical research, enhancing pain management solutions for patients across Malaysia and ASEAN. We are dedicated to empowering future healthcare leaders,” said Dr. Isaac R. Joseph, Director of AdipoLABs Healthcare (M) Sdn Bhd.

In a parallel effort to advance physiotherapy education, AdipoLABs Malaysia, Red & Blue Co., Ltd., and UoC signed a second MoU focused on knowledge transfer and medical device donation. Under this agreement, AdipoLABs Malaysia will donate a Pain Bot unit to UoC, giving students access to cutting-edge pain detection and treatment technology and enhancing their knowledge and skills in innovative musculoskeletal pain management methods.

AdipoLABs, a Ministry of Health (MOH)-registered medical-device establishment under the Medical Device Authority(MDA), anchors this collaboration with proven regulatory credibility and a strong commitment to quality and innovation. Their certified standing reinforces UoC’s ambition to accelerate evidence-based research and industry-ready healthcare solutions.

“AdipoLABs’ partnership with the University of Cyberjaya is more than a collaboration, it is a direct investment in the next generation of healthcare professionals. With the introduction of advanced rehabilitative technologies, our students gain access to international-standard tools and real-world innovation that will shape their confidence, competence, and future careers,” said Professor Dr. David Whitford, Vice-Chancellor of the University of Cyberjaya.

Further strengthening this collaboration, Professor Dr. Yoo Seung-mo from South Korea, the inventor of the Pain Bot, will serve as an Adjunct Professor at UoC. Dr. Yoo will provide on-site training and ongoing remote mentorship, ensuring students receive the highest level of expertise in utilising the Pain Bot technology and applying advanced pain detection and treatment techniques.

Together, UoC and AdipoLABs are positioned to drive forward Malaysia’s healthcare innovation agenda with greater confidence and impact.

For more information on University of Cyberjaya or AdipoLABs Healthcare (M) Sdn Bhd, kindly visit: University of Cyberjaya – Premier University in Malaysia or adipolabs-msia.com – AdipoLABs Healthcare Malaysia

ABOUT UNIVERSITY OF CYBERJAYA (UOC)

The University of Cyberjaya is a premier institution located in Malaysia’s first smart city, offering a transformative educational experience on a state-of-the-art, eco-friendly campus. The University was recently ranked in the top 1,000 universities in the world under the QSWorld University Rankings and is also currently ranked top 450 under the QS Asia University Rankings 2026.

The University is renowned for its excellence in medicine, teaching, employability, facilities, and social responsibility. Additionally, it holds a Top 601+ ranking in the Times Higher Education Sustainability Impact Rankings, excelling in Top 200 for Good Health and Well-being (SDG 3).

Founded in 2005 with a focus on medicine and pharmacy, the University has expanded to offer over 50 programmes across diverse fields such as medicine, health sciences, nursing, pharmaceutical sciences, psychology, business, and biomedical engineering. With a global community of over 10,000 students and over 13,000 alumni, the University is shaping future leaders who are making significant contributions to various industries. The University’ impact is reflected in its graduates, who have contributed to innovations in healthcare during the COVID-19 pandemic, participated in international humanitarian missions, and made significant advancements across industries such as business and biomedical engineering.

The University is guided by Chancellor Tan Sri Dato’ Seri Dr. Noor Hisham Abdullah, a prominent figure in global healthcare

for World Health Organization (WHO) initiatives and former Director-General of the Malaysian Ministry of Health. Chairman Professor Tan Sri Dato’ Dr. Mohd Amin Jalaludin, former Vice-Chancellor of the University of Malaya, provides strategic governance as Chairman of the Board of Governors. Under the leadership of Vice Chancellor Professor Dr. David Whitford, the University is strengthening its global outlook and academic excellence. The university can be contacted at +603 8313 7000.

About AdipoLABs Co., Ltd.

AdipoLABs Co., Ltd. is a South Korean medical device company specialising in innovative hyperthermia cancer treatment technology. The company is the manufacturer of the Remission 1℃, a high-frequency hyperthermia device used in hospitals worldwide as an adjunct therapy for cancer treatment. With a commitment to research and development, AdipoLABs strives to improve patient outcomes and contribute to a future free from the burden of disease. AdipoLABs has a global presence, with branches in India, China, and Malaysia.

About AdipoLABs Healthcare (M) Sdn Bhd

AdipoLABs Healthcare (M) Sdn Bhd, established in Malaysia in 2018, is a subsidiary of AdipoLABs Co., Ltd. As the sole distributor of AdipoLABs medical devices in Malaysia and authorised representative for sales, marketing, and after-sales service throughout the ASEAN region, the company is committed to bringing innovative, non-invasive medical devices and innovative solutions to the Southeast Asian market. The company works closely with an international team of researchers, doctors, lab technicians, and engineers to provide cutting-edge healthcare technology to the ASEAN market. Dr. Isaac R. Joseph and Mr. Moses Balagopal are the Directors and Co-founders of AdipoLABs Healthcare (M) Sdn Bhd.

About Red & Blue Co., Ltd.

Red & Blue Co., Ltd. is a South Korean company specialising in the development and distribution of advanced medical devices and healthcare solutions. As a key partner of AdipoLABs Co., Ltd., Red & Blue Co., Ltd. is committed to supporting education and training initiatives that promote the effective use of innovative pain detection and pain treatment techniques. Dr. Yoo works closely with healthcare professionals and academic institutions to advance the field of pain management and improve patient outcomes.

Issued by MNAIR PR Consultancy Sdn Bhd on behalf of University of Cyberjaya and AdipoLABs Healthcare (M) Sdn Bhd Contacts for Media Enquiries:

MNAIR PR Consultancy Sdn Bhd Ameera Hani
Associate Director, Public Relations
+6014 2243296
ameera@mnairpr.com

University of Cyberjaya (UoC) Ehya Nadzeri
Communications
Cyberjaya Education Group Berhad
gcmc@cyberjaya.edu.my

Kangji Medical and Knight Bidco Jointly Dispatch Scheme Document for Privatisation Proposal

Kangji Medical Holdings Limited (Kangji Medical or the Company, HKG: 9997) and Knight Bidco Limited (the Offeror) today announced that a circular in relation to the proposed privatisation of Kangji Medical (the “Scheme Document) has been published, setting out the terms and conditions of the proposed privatisation of Kangji Medical (the Proposal) by way of a scheme of arrangement.

The document is now available on the Stock Exchange of Hong Kong’s website. (website link)

The Proposal represents an attractive opportunity for Scheme Shareholders to realise their investment in the Company with certainty amidst market volatility, potential geopolitical risk, industry and macro uncertainty.

Recommendation
The Independent Board Committee (“IBC”), having considered the Proposal, the Scheme, and the Special Deal, and having taken into account the advice of the Independent Financial Adviser, considers that the Proposal, the Scheme, and the Special Deal are fair and reasonable insofar as the Independent Shareholders are concerned.

Accordingly, the IBC recommends that the Independent Shareholders vote in favour of various resolutions to render the Scheme effective.

Further information on the reasons for the IBC’s recommendation, and the Independent Financial Adviser’s report are available in the Scheme Document.

Action required by Scheme Shareholders
All shareholders are advised to review the Scheme Document. Shareholders should refer to the Scheme Document for further information regarding the Proposal, the Scheme and the Special Deal, as well as the Notices of the Court Meeting and the EGM, together with the forms of proxy in relation thereto.

In accordance with the directions of the Grand Court, the Court Meeting will be held at 10:00 a.m. (Hong Kong time) on 10 November 2025 at United Conference Centre, 10/F, United Centre, 95 Queensway, Admiralty, Hong Kong. The EGM will be held at the same place and on the same date at 10:30 a.m.

Kangji Medical shareholders should carefully read the Scheme Document in its entirety before making a decision with respect to the Scheme.

Background to the Proposal

On 17 July 2025, the Offeror requested the Board to put forward the Proposal to the Shareholders for the privatisation of the Company by way of a scheme of arrangement under section 86 of the Companies Act. Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror and the listing of the Shares will be withdrawn from the Stock Exchange.

Kangji Medical Holdings Limited
Kangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specialize in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”) . It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.

About Knight Bidco Limited
Each of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the Latest Practicable Date, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the Latest Practicable Date, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the Latest Practicable Date, save as disclosed in the section headed “11. Shareholding Structure of the Company” in Part VII – Explanatory Memorandum of the Scheme Document, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.

Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Scheme Document.

Each of the Founder Entities is a business company incorporated in the British Virgin Islands.

Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).

TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.

NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).

Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.

Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the Latest Practicable Date, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.

All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Scheme Document dated 13 October 2025. This press release should be read in conjunction with the Scheme Document, a copy of which is available on (website link).

Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical’s Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the Proposal).

Proposed privatisation of Kangji Medical Holdings Limited

The Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022
The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal
The Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidity

Aug 12 2025, Kangji Medical Holdings Limited (Kangji Medical or the Company, HKG: 9997.HK) and Knight Bidco Limited (the Offeror) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.

Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.

The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding.

Rationale for the Proposal

Due to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.

In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company’s long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.

Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.

Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.

Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:

(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;
(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and
(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.

In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.

Overview of the Proposal

The proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]

The Offeror has indicated the Cancellation Price is final and will not be increased further.

The Cancellation Price reflects:

A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).
A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.
An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.
A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).

The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.

The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.

Scheme Meeting

Details of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.

There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.

Irrevocable Undertaking

An Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.

Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.

J.P. Morgan acted as the exclusive financial advisor to the Offeror.

Kangji Medical Holdings Limited

Kangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.

About Knight Bidco Limited

Each of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.

Each of the Founder Entities is a business company incorporated in the British Virgin Islands.

Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.

[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85

All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf.

Cornerstone Robotics Completes World’s First Clinical Validation of Autonomous Surgery Performed by Robot-Assisted Surgery

A major breakthrough in surgical embodied intelligence in Robot-Assisted Surgery (RAS) has been achieved in Hong Kong, China. At a press conference held on 5 August, the Chinese University of Hong Kong (CUHK) officially announced that its multidisciplinary research team, in collaboration with Cornerstone Robotics, a leading global innovator and unicorn enterprise in surgical robotics, has successfully developed the world’s first embodied intelligence platform for multitask surgical automation. The team also completed the world’s first clinical validation of autonomous surgery using this platform on Cornerstone Robotics’ self-developed Sentire® Endoscopic Surgical System.

The research paper, titled “Surgical Embodied Intelligence for Generalized Task Autonomy in Laparoscopic Robot-assisted Surgery“, has been published in Science Robotics, a prestigious research journal in the field of robotics and a flagship publication under the Science family. With a current impact factor of 27.5 and a five-year impact factor of 32.9, Science Robotics is one of the most influential journals in the global robotics field. This marks the first successful in vivo animal testing using a Chinese-developed laparoscopic surgical robot equipped with AI-powered embodied intelligence, validating its multitask autonomy and human-robot collaboration capabilities. It demonstrates the generalisability of the algorithms and the system’s clinical feasibility, paving the way for a future of smarter, more collaborative, and more accessible robotic surgery.

A Breakthrough Framework: VPPV Embodied Intelligence
The research introduced a novel paradigm for surgical task automation, encompassing visual parsing, a perceptual regressor, policy learning, and a visual servoing controller (VPPV). This framework combines robust visual foundation models, the generalisation capability of reinforcement learning, and integration of data-driven policy and classic controller to achieve breakthroughs in autonomous performance of robot-assisted surgery, particularly regarding stability, flexibility, and repeatability. Unlike traditional methods in autonomous surgery that rely on additional sensors or pre-defined models and rules, this research is the world’s first purely vision-based surgical embodied intelligence framework, featuring full perception, multitask applicability, precise closed-loop servo control, and human-robot cooperation functions. It significantly lowers the barrier for R&D and clinical adoption, setting a new benchmark for next-generation intelligent surgical assistants.

The research team trained multiple AI frameworks with generalized task autonomy using their independently developed open-source surgical embodied intelligence simulator, SurRoL, and successfully achieved zero-shot sim-to-real transfer. SurRoL integrates multimodal sensing, built-in physics engine modelling, and multi-task operation training, encompassing the robot-assisted surgery control interface, simulation environment, and reinforcement learning engine.

Ex and In Vivo Validation on the Sentire® Endoscopic Surgical System
To simulate real surgical settings, the research team conducted rigorous experiments using ex vivo porcine stomach tissue (preserving the left and right gastroepiploic arteries) and an in vivo ~30kg pig. Both tests were completed using the Sentire Endoscopic Surgical System, fully developed by Cornerstone Robotics. During the in vivo validation phase, an innovative supervised autonomy safety mode was adopted. Without any external sensors and relying solely on the Sentire Endoscopic Surgical System’s high-definition stereoscopic endoscope system, the robot autonomously executed several surgical assistive tasks, such as gauze picking, soft tissue retraction, and blood vessel clipping. The system demonstrated robust adaptability to environmental changes, reliable control stability, and clinical translation potential, offering tangible support for the surgical embodied intelligence mode driven by human-robot collaboration.

A Vertically Integrated, AI-Ready Robotic Platform
Dr. Jerry Wang, Co-Founder, Chief Technology Officer, and Chief Operating Officer of Cornerstone Robotics, and the corresponding author of the study, stated, “The Sentire Endoscopic Surgical System, as a core platform in this research, is built on a fully self-developed infrastructure-including mechanical, electrical, software architecture, robotic algorithms, imaging systems, and advanced energy control. This commercial-grade integrated robotic system provides the technical robustness and precision needed for stable deployment of AI autonomy in dynamic surgical environments.”

He added, “At Cornerstone Robotics, we remain committed to the R&D strategy of full-stack independent research and vertical integration. Our proprietary technology, independently developed software, hardware and system integration, benefits our core platforms with exceptional scalability, with built-in AI-readiness and AI-friendly architecture. This not only enables rapid adaptation and deployment of AI algorithms but also allows the system to flexibly address diverse surgical tasks and scenarios, laying a solid foundation for the evolution of intelligent surgery.”

From Lab to Operating Room: A Leap Toward Clinical Translation
As a key technology partner in the research, the Cornerstone Robotics team worked closely with CUHK researchers to complete the successful deployment of algorithms and their in vivo validation on the Sentire® Endoscopic Surgical System. This achievement not only validates the open-source infrastructure and high compatibility of Cornerstone Robotics’ platform but also marks a significant advance in accelerating AI-powered surgical assistance from the lab to the forefront of clinical translation.

Professor Samuel Au, Founder and CEO of Cornerstone Robotics, commented, “We firmly believe that deep integration between research and industry is the driving force behind breakthroughs in advanced medical technologies. This collaboration not only validates the real-world application of embodied AI on a commercial robotic surgical platform but also showcases their vast potential in surgical automation. We will continue to work with international researchers and clinical partners to explore new eras in task automation, human-robot collaboration, and intelligent system monitoring mechanisms, to accelerate the path toward real clinical application of smart surgical robots.”

About Cornerstone Robotics Limited (CSR)
Cornerstone Robotics (CSR) is a unicorn enterprise, leading medical innovations to create a healthier world. It advances surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. Founded in 2019, CSR has assembled a global team of surgical robotics experts, clinical professionals, and multidisciplinary innovators, driving rapid growth with key hubs in Hong Kong, Shenzhen, Beijing, Shanghai, and Boston (US), alongside an R&D collaboration hub in Portsmouth (UK). With multiple development pipelines, we are pioneering robotic solutions for soft tissue and other surgical specialties.

To find out more information, please visit our website at https://en.csrbtx.com/.

Avantor Relocates Korea Office in Suwon to Support Growth and Enhance Collaboration

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, has inaugurated its new office in Suwon, Korea. The office relocation reflects Avantor’s continued investment in the Asia Pacific region and its commitment to providing a modern, collaborative workspace for associates.

The new office space is designed to enhance collaboration, drive innovation and build closer customer relationships. With this relocation, Avantor is better positioned to continue serving the fast-evolving Korean market while advancing its global mission of setting science in motion to create a better world.

Company leaders, including Benoit Gourdier, Executive Vice President, Biopharma Production Segment; Christophe Couturier, Executive Vice President, AMEA Region; and Narayana Rao Rapolu, Senior Vice President, Global Bioprocessing Commercial, joined the office opening, underscoring Korea’s strategic importance within Avantor’s global operations.

“Establishing our new office in Suwon is a strategic move that strengthens our presence in one of Asia’s most dynamic markets,” said Christophe Couturier, Executive Vice President, AMEA Region. “This space enables our teams to stay closely connected to our customers’ evolving needs and reinforces our ability to deliver tailored solutions that drive meaningful outcomes in the Asia Pacific region.”

About Avantor

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Regional Media Contact:

Swati Chhabra
Manager – Corporate Communications, AMEA
Avantor
+91 9958404334
swati.chhabra@avantorsciences.com

Global Media Contact
Eric Van Zanten
Head – External Communications
Avantor
eric.vanzanten@avantorsciences.com

CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets

On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited (“CMS” or the “Group”) on the Main Board of the Singapore Exchange (“SGX”), SGX and CMS co-hosted the “Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner”. Held in a grand fashion, the event was held at the Group’s CDMO manufacturing facility, PharmaGend, which is located in Tuas, Singapore.

The event brought together about 150 representatives from local government agencies, multinational pharmaceutical companies, innovative biotech companies, leading investment institutions, and the KOLs in the pharmaceutical industry. Through a series of insightful keynote speeches and panel discussions, guests engaged in in-depth exchanges and shared ideas on various topics, such as the pharmaceutical industry’s development in Singapore and emerging markets across the Asia-Pacific region, the breakthroughs and overseas expansion of Chinese innovative drugs, the globalization strategies, commercialization pathways, as well as ecosystem collaboration of innovative pharmaceutical companies.

The forum began with opening remarks by Ms. Caihan Chia, Head of Greater China Capital Markets and Chief Representative of Beijing Representative Office at SGX, and Ms. Louise Ho, Assistant Vice President of Healthcare Division and China Desk at the Singapore Economic Development Board. These were followed by keynote addresses from Mr. Siang Sheng Foo, Head of Investment Banking at Singapore CGS International Securities, Mr. Shriharsha Sarkar, Partner for Asia Healthcare at L.E.K. Consulting, and Ms. Kah Yean Neo, Senior Director at Singapore’s Agency for Science, Technology and Research (A*STAR).

Ms. Caihan Chia stated that in recent years, SGX has become increasingly attractive to Chinese enterprises through policy refinements, including tax incentives, capital support from the secondary market, and streamlined regulatory procedures. The successful listing of CMS showcases the growing interest among Chinese companies in the Singapore market. As one of leading healthcare companies, CMS’s listing highlights the growing demand for medical innovation and medical service accessibility across Asia. With CMS seeking to expand its business in Southeast Asia, its listing on SGX will serve as a strategic springboard to connect with international investors and further reinforce Singapore’s role as a vital capital hub.

Emerging Markets: A New Growth Engine for the Global Pharmaceutical Industry

Emerging markets, such as Southeast Asia and the Middle East, are becoming new growth drivers for the global pharmaceutical industry. A combination of factors, including large populations, early signs of ageing, the rise of the middle class, growing health awareness, and the increasing burden of chronic diseases, is driving higher demand for medicines and improved accessibility. According to IQVIA, by 2028, the combined pharmaceutical market size of four major emerging regions – Asia-Pacific, India, Africa & the Middle East, and Latin America – is expected to reach USD 336 – 384 billion, comparable to the USD 410 billion market size projected for Western Europe.

Singapore possesses geographical and institutional advantages for accessing Southeast Asia, the Middle East, and other emerging markets. With its robust financial system, open and inclusive policy environment, and thriving pharmaceutical industry, Singapore is increasingly becoming a global hub for capital and innovation. It has also become the preferred location for regional headquarters for many Chinese enterprises expanding into Southeast Asia.

Seizing Opportunity: Strategic Pathways for Chinese Innovative Pharma to Expand into Emerging Markets

In Southeast Asia’s six major economies (SEA6), limited healthcare coverage means that out-of-pocket payments constitute the primary source of drug expenditure. While generics dominate, branded originator drugs continue to hold significant market share in private hospitals, retail pharmacies, and clinics. Patient demand for biologics and biosimilars continues to grow.

In terms of commercialization models, traditional distribution model, which relies on third-party logistics (3PL), is gradually giving way to models with stronger commercial capabilities and strategic licensing partnerships. To achieve sustainable success in Southeast Asia, pharmaceutical companies must build competitive product portfolios, leverage experienced local sales teams, and consider establishing localized manufacturing capabilities, widely seen as key strategic advantages.

The CMS’s Approach: Building Dual Hubs in China and Singapore to Drive End-to-End Innovation

With over 30 years of experience in the Chinese market, CMS has accumulated a differentiated product portfolio and mature commercialization capabilities. Today, the Group is expanding its strategic vision across the Asia-Pacific region, using China as a foundation and Singapore as its regional hub. Through an end-to-end value chain of “R&D–manufacturing–commercialization–investment”, CMS is driving innovation to deliver high-quality pharmaceutical products and services to patients worldwide.

Mr. Lam Kong, Chairman, Chief Executive and President of CMS, delivered a keynote speech titled “New CMS, New Ascent: Three Strategies to Drive the Second Growth Curve.” He shared that since launching its “New CMS” transformation strategy in 2018, the Group has propelled growth through three engines — product innovation, commercial transformation, and international expansion. This has enabled the Group’s transition from “China’s largest CSO” to “a pharmaceutical company in transformation,” and finally, to “an end-to-end innovative pharmaceutical enterprise”, with a sustainable second growth curve.

In product innovation, driven by a three-dimensional approach of “Licensing, Strategic partnerships, and in-house R&D”, the Group has built a pipeline of nearly 40 FIC/BIC innovative drugs, five of which have been approved in China and are in large-scale clinical use. In the area of commercialization, CMS remains focused on cardio-cerebrovascular, gastroenterology, ophthalmology, and skin health specialties, while enhancing anti-cyclical resilience through a diversified ecosystem of “New retail, E-commerce, and Consumer healthcare”. Its skin health subsidiary, Dermavon, has become a niche market leader in China and is now progressing toward a spin-off for an independent listing on the Hong Kong Stock Exchange. In the area of globalization, CMS is creating a dual-track model centred in China and Singapore, using a strategy of “bringing in” to accelerate overseas product launches in China, and a strategy of “moving outward” to establish an end-to-end presence in emerging markets. The successful listing on SGX will enhance its regional synergy and close the loop in the “R&D – Manufacturing – Commercialization – Investment” global value chain, unlocking growth from emerging markets and creating a multi-regional growth framework.

CMS formally launched its industrial globalization strategy in 2022. At this event, CMS’s international business clusters made their debut, showcasing its forward-looking, full industry chain layout and leadership in setting a new paradigm for Chinese pharmaceutical companies expanding overseas.

PharmaGend

Established in 2023, PharmaGend aims to become Southeast Asia’s largest and most reliable CMO/CDMO. It has a site spanning 30,000 square meters and is capable of manufacturing dosage forms such as tablets and capsules, which has been certified by the FDA and HSA, demonstrating its high-standard pharmaceutical manufacturing capabilities for global export. It has future plans to expand production lines for injections, ointments, and nasal sprays.

Rxilient

Established in 2021, Rxilient operates by a professional and experienced localized team, and has fully established BD, registration, marketing, andcommercialization capabilities. Leveraging its unique local expertise and advantages, Rxilient can bring innovative drugs to emerging markets led by Southeast Asia and the Middle East. It has submitted marketing applications for nearly 20 drugs and medical devices across Southeast Asia, the Middle East, and regions such as Hong Kong, Macao, and Taiwan, covering the therapeutic areas of dermatology, ophthalmology, oncology, autoimmune, and central nervous system. As more drugs receive regulatory approval in these countries, Rxilient anticipates sustained and significant revenue growth.

CMS R&D

Established in Singapore in 2024, CMS R&D has been working on more than 10 early-stage innovative drug projects. Leveraging China’s mature early-stage R&D and clinical resources, it aims to synchronize China speed with global standards to advance more Chinese innovative drugs toward globalization.

HiGend

Established in 2025, HiGend is a global early-stage bio-pharma incubation platform which uses a “hub-and-spoke” model, integrating China’s innovation capabilities to accelerate global R&D and commercialization.

Subsequently, three panel discussions were held in succession, which facilitated an in-depth exchange between industry and capital, driving the forum to its climax. Distinguished guests from various parties freely shared insights on the continuous development and diversification of the pharmaceutical ecosystem, and jointly explored the future of pharmaceutical expansion into emerging markets.

Panel Discussion 1 – Challenges and Breakthroughs: The Enduring Power of Organizational and Strategic Long-Term Vision

The emerging markets of today share numerous similarities with China’s pharmaceutical landscape twenty years ago, which are currently experiencing a critical period of accelerated demand release for pharmaceuticals, constituting medium- to long-term structural opportunities. Undoubtedly, these markets are diverse and complex — each country has its own unique characteristics in terms of drug regulation, healthcare insurance mechanisms, and market acceptance. However, CMS’s core strength lies in its systematic commercialization capabilities, which it is now extending to emerging markets. CMS’s senior management team, alongside its business partners, jointly reviewed and discussed the key factors contributing to its commercial excellence, as well as the pathways driving the Group’s second growth curve.

The first panel discussion was moderated by Mr. Brian Yang, Vice President for Business Development at Rxilient. Participants included Mr. Karl Luschmann, Managing Director of Pharma Stulln GmbH, and Ms. Linlang Wang (formerly the first product manager of the Augentropfen Stulln Mono Eye Drops (“Stulln”) in China), General Manager of CMS’s ophthalmology business, CMS Vision, among others. Collectively, they reviewed the core strategies behind the rapid, year-on-year growth of Stulln in the Chinese market- a focus on clinical value and continuous innovation in commercialization models. CMS adhered to prioritizing clinical efficacy, amassing substantial evidence to demonstrate the clinical value of Stulln in treating asthenopia, and leveraging medical advancements to drive product commercialization. Meanwhile, CMS also continuously revamped its commercialization model by establishing a full-channel retail system that integrates in-hospital and out-of-hospital sales, developing an “online + offline” omnichannel marketing system, and adopting a diversified product portfolio strategy in consumer attributes. These concerted efforts facilitated the sustained, rapid growth and wide recognition of Stulln within the Chinese market.

Mr. Victor Yin, Country Manager of Incyte Bioscience China, Mr. Huang Anjun, CEO of Dermavon (CMS’s skin health business), and Mr. Lawrence He, CEO of Rxilient, jointly retraced the entire journey of launching ruxolitinib cream — a blockbuster prescription drug with consumer attributes. From the signing of the collaboration agreement and pilot launch in Hainan Boao Lecheng pilot zone, to marketing approvals in Macao, followed by Hong Kong, introduction into designated hospitals in the Greater Bay Area in China, and the NDA has been submitted in China, Singapore, and other countries or regions. Leveraging mature clinical development experience and capabilities, proven commercialization competence, a compliant operational system, and efficient execution, the group earned high recognition and trust from Mr. Victor Yin.

Together, the parties have helped bring new hope to vitiligo patients in both China and Southeast Asia simultaneously.

These successful commercialization experiences not only provide valuable business model references for international pharmaceutical companies entering the Chinese market, but also offer significant insights for Chinese pharmaceutical companies looking to expand into emerging markets overseas.

Panel Discussion 2 – Breaking Through: Diverse Explorations for Chinese Innovative Pharmaceutical Companies to Expand into Emerging Markets

Over the past three years, Chinese pharmaceutical companies have secured over USD 10 billion in upfront payments through license-out deals. However, the majority of these transactions remain concentrated in mature markets led by Europe and the United States. Looking ahead, the next engine of growth may shift toward emerging markets such as Southeast Asia, the Middle East, and Latin America — regions with a combined population of approximately 1.8 billion and per capita healthcare spending is merely one-fifth that of Western markets. While pharmaceutical demand is accelerating in these areas, challenges persist, including limited payment capacity and significant differences in regulatory systems. Whether Chinese pharmaceutical companies can effectively replicate and localize their domestic development and innovation models in these blue ocean markets, will determine the scale and sustainability of their second growth curve.

The second panel discussion, moderated by Mr. Brian Yang, featured esteemed representatives from leading Chinese innovative pharmaceutical companies that are closely collaborating with CMS, including Tibet Nordicon Pharma, NeuroDawn Pharmaceutical (Ningdan Pharmaceutical), Mabgeek Biotech, and Jingze BioPharmaceutical. Using examples such as XinHuoSu (for acute decompensated heart failure), Y-3 for Injection (under development for stroke treatment), ABP-671 (under development for gout) etc., participants held in-depth discussions on topics, including “What constitutes truly clinically valuable innovation” and “How to implement commercialization pathways within emerging markets”

True innovation value stems from professionalism and dedicated focus. It requires researchers to remain committed to a specific field over the long term, and to validate new targets and drug structures through reverse translational research, thereby identifying their potential clinical value. Since China officially joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 2017 and became a member of its steering committee, the quality of Chinese innovative pharmaceutical products has improved rapidly and has gradually gained global recognition. In addition to entering mature markets led by Europe and the U.S., Chinese innovators are increasingly turning their attention to emerging blue ocean markets such as Southeast Asia, actively exploring parallel regulatory filings in both emerging and mature markets. For innovative pharmaceutical companies, globalization strategies should be integrated into the early stages of pipeline development cycles and macro-level strategy. It is also crucial to seek out a business partner that possesses the entire value-chain capabilities — including experienced local clinical registration teams, manufacturing capacity, and commercialization operations—in order to drive efficient product launches and expand access to high-quality medical solutions across a broader range of geographies.

Panel Discussion 3 – Setting Sail: Pharmaceutical Expansion into Emerging Markets

The third panel discussion was moderated by Mr. Frank Hong, Managing Director of Legend Capital, engaging multiple leading pharmaceutical analysts from renowned investment banks and representatives from investment institutions in an insightful sharing and in-depth discussion on the international expansion of innovative drug products and pharmaceutical industry globalization. Participants pointed out that China’s pharmaceutical industry is currently at a strategic inflection point for global expansion. The Intellectual Property (IP) licensing model has preliminarily demonstrated the global competitiveness of Chinese innovation. However, for most domestic pharmaceutical companies, this process remains in the “isolatedbreakthrough” phase. To achieve the transition from a practice of “one-time licensing” to “sustained global engagement,” Chinese pharmaceutical companies must look to multinational pharmaceutical giants as a benchmark — internationalizing their commercialization, manufacturing, and R&D capabilities to build a replicable, scalable, and sustainable global industrial ecosystem.

Achieving this goal is no easy task. While many Chinese pharmaceutical companies have begun exploring emerging markets, they often face challenges such as fragmented distribution channels and difficulty in standardizing operational systems. Only by maintaining conviction and building a fully integrated, internationalized ecosystem across the entire value chain can companies transform one-off licensing revenues into long-term brand equity and control of the value chain, ultimately earning a sustained voice and competitive edge in the global arena.

Though the forum’s spotlight has dimmed, the consensus reached continues to shine like a beacon: Southeast Asia, the Middle East, and other emerging markets are quickly becoming the next major destinations for the global pharmaceutical industry. CMS’s fully localized framework covering “Research, Manufacturing, Commercialization, and Investment” has paved the way for industrial expansion overseas, constructing a bridge to globalization. With an open and win-win attitude, the Group welcomes innovators, regulators, and capital from around the world to work together in bringing more Chinese and global innovative drugs to emerging markets, fostering international growth. CMS sincerely invites partners across all sectors to seize the growth opportunities of the Asia-Pacific region and jointly promote innovation in the pharmaceutical industry across emerging markets, so that more innovative therapies may benefit patients around the world.

Media Contact:

Company: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore

Cornerstone Robotics (CSR), a leading medical innovator in precision surgical systems, signed a tripartite Memorandum of Understanding (MOU) with the National Healthcare Group PTE LTD (NHG Health) and the Lee Kong Chian School of Medicine (LKCMedicine) of Nanyang Technological University, Singapore to facilitate healthcare advancement in Singapore through collaboration in robotic-assisted surgery (RAS) in clinical research and application, surgical education, and healthcare innovation.

Front row (from Left): Alexis Cheng, Co-Founder & Vice President of Operation and Business Strategy of Cornerstone Robotics, Professor Joe Sim, Group CEO, NHG, Professor Joseph Sung, Dean, Lee Kong Chian School of Medicine; Back row (from left): Jerry Wang, Co-Founder, CTO & COO of Cornerstone Robotics, Professor Lam Khin Yong, Vice President (Industry), Mr. Ong Ye Kung, Minister of Health and Coordinating Minister for Social Policy, Mr. Tan Tee How, Chairman, NHG

RAS is an important pillar of minimally invasive care. It is reshaping the field by improving precision in surgery through adopting high resolution imaging, smart algorithms, and the finest control of instruments, RAS results in better patient outcomes such as less invasiveness and fast recovery.

As an innovator in this transformation, Cornerstone Robotics’ Sentire® Endoscopic Surgical Robot (C1000) is wholly developed in-house. It has completed clinical trials in Mainland China and Hong Kong and has received National Medical Products Administration (NMPA) approval for clinical applications.

The MOU represents a significant milestone in Cornerstone Robotics’ vision of “forging accessibility of robotic surgery” alongside its partnership with the Faculty of Medicine of The Chinese University of Hong Kong (CUHK).

Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said, “We are honoured to collaborate with NHG Health and LKCMedicine to further advance RAS in Singapore. By integrating precision engineering, intelligent algorithms, and insights from frontline surgeons, Cornerstone Robotics is dedicated to making advanced surgical robotic technology accessible to patients around the world.”

Looking ahead, the three parties will continue to strengthen their collaboration to drive innovation, expand clinical impact, and cultivate surgical talent — working together to shape a smarter, more accessible future for surgical care across the region and beyond.

About Cornerstone Robotics Limited (CSR)

Cornerstone Robotics (CSR) is leading medical innovations to create a healthier world by advancing surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient for everyone globally. Founded in 2019, CSR has assembled a global team of surgical robotics experts, clinical professionals, and multidisciplinary innovators, driving rapid growth with key hubs in Hong Kong, Shenzhen, Beijing, Shanghai, Boston (US), and Amsterdam (NL), alongside an R&D collaboration hub in Portsmouth (UK). With multiple development pipelines, we are pioneering robotic solutions for soft tissue and other surgical specialties.

To find out more information, please visit our website at https://en.csrbtx.com/ .

About NHG Health

NHG Health is a leading public healthcare provider in Singapore recognised for its quality clinical care and its commitment in enabling healthier lives through preventive health, innovative solutions and person-centred programmes tailored to every life stage. Our integrated health system, which spans primary care, hospitals and national specialty centres, includes Tan Tock Seng Hospital, Khoo Teck Puat Hospital, Woodlands Health, Yishun Community Hospital, NHG Polyclinics, the Institute of Mental Health, National Skin Centre and the National Centre for Infectious Diseases. Together with academic and industry partners, we advance medical education, research and healthcare innovation in Singapore, addressing areas that are critical to Singapore’s population needs. As the Regional Health Manager for Central and North Singapore, NHG Health partners general practices and health and social care agencies to ensure the physical, mental and social well-being of residents in the community. Together, we are committed to building healthier and resilient communities and Adding Years of Healthy Life to the people we serve.

More information at www.nhghealth.com.sg.

About Nanyang Technological University, Singapore (NTU Singapore)

A research-intensive public university, Nanyang Technological University, Singapore (NTU Singapore) has 35,000 undergraduate and postgraduate students in the Business, Computing & Data Science, Engineering, Humanities, Arts, & Social Sciences, Medicine, Science, and Graduate colleges. NTU is also home to world-renowned autonomous institutes – the National Institute of Education, S Rajaratnam School of International Studies and Singapore Centre for Environmental Life Sciences Engineering – and various leading research centres such as the Earth Observatory of Singapore, Nanyang Environment & Water Research Institute and Energy Research Institute @ NTU (ERI@N). Under the NTU Smart Campus vision, the University harnesses the power of digital technology and tech-enabled solutions to support better learning and living experiences, the discovery of new knowledge, and the sustainability of resources. Ranked amongst the world’s top universities, the University’s main campus is also frequently listed among the world’s most beautiful. Known for its sustainability, NTU has achieved 100% Green Mark Platinum certification for all its eligible building projects. Apart from its main campus, NTU also has a medical campus in Novena, Singapore’s healthcare district.

For more information, please visit website www.ntu.edu.sg.

Cornerstone Robotics Launches First Clinical Evaluation of its Hong Kong-Developed Surgical Robotic System in UK

Cornerstone Robotics (CSR) has announced the first formal clinical investigation of its Hong Kong-developed surgical robotic system at Portsmouth Hospitals University NHS Trust (PHU), Portsmouth, UK. The Sentire® Endoscopic Surgical System (C1000), developed by Hong Kong-based Cornerstone Robotics Limited, is now being evaluated at PHU’s Queen Alexandra Hospital in Portsmouth, UK.

This groundbreaking initiative represents the first clinical deployment of the Sentire® System in the UK and Europe, a major milestone in international clinical collaboration that marks the start of Cornerstone’s preparations for commercial activities in the region.

Led by Professor Jim Khan, PHU’s surgical team kicked off the start of the clinical trial with three successful colorectal procedures using the Sentire® system.

The clinical investigation is focused on assessing the safety and efficacy of the Sentire® system for performing colorectal and urological procedures within European populations—expanding upon previous clinical data generated in Asia. The trial follows international standards for device evaluation, marking a significant regulatory and clinical first for a Chinese robotic platform.

“I was particularly impressed by how quickly our team adapted to the Sentire® Surgical System,” said Professor Jim Khan, Chief Investigator. “The platform performed smoothly and reliably. I’d like to thank the Cornerstone team for their outstanding support throughout this pioneering phase.”

Professor Samuel Au, CEO of Cornerstone Robotics, commented: “This is a proud moment for our company and for the broader innovation ecosystem in Hong Kong. We are honoured to partner with PHU in launching this CSR’s first investigation in the UK. We believe the results will further validate the capabilities of the Sentire® Endoscopic Surgical System and help deliver greater accessibility and efficiency in surgical robotics in the UK, EU, and beyond.”

The Sentire® Endoscopic Surgical System combines clinical workflows with integrated engineering, software, and imaging technologies to support surgeons in performing intricate minimally invasive procedures. Early clinical feedback suggests that these features may contribute to streamlined workflows for surgical teams and improved outcomes for patients.

This collaboration reinforces PHU’s position at the forefront of surgical robotics. PHU is the first in the UK to operate a dedicated robotic-assisted day surgery programme and has performed over 5,000 robotic procedures across colorectal, urological, upper gastrointestinal, and gynaecological specialities – offering a scalable model for NHS adoption of advanced surgical technology.

About Portsmouth Hospitals University NHS Trust (PHU)
Portsmouth Hospitals University NHS Trust (PHU) delivers acute hospital services to over 675,000 people across Hampshire. Based at Queen Alexandra Hospital, PHU is an international leader in surgical robotics, having pioneered minimally invasive surgery since early the 2000s.

PHU has been of the earliest adopters of robotics since 2012 and has completed more than 5,000 robotic procedures across multiple specialties helping to redefine surgical care across the NHS. PHU also leads research in clinical robotics with the adoption of the UK’s first robotic-assisted day case surgery programme.

About Cornerstone Robotics Limited (CSR)
Cornerstone Robotics (CSR) is leading medical innovations to create a healthier world by advancing surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient for everyone globally. Founded in 2019, CSR has assembled a global team of surgical robotics experts, clinical professionals, and multidisciplinary innovators, driving rapid growth with key hubs in Hong Kong, Shenzhen, Beijing, Shanghai, Boston (USA), and Amsterdam (NL), alongside an R&D collaboration hub in Portsmouth (UK). With multiple development pipelines, we are pioneering robotic solutions for soft tissue and other surgical specialties. See https://en.csrbtx.com.

Contact:
Cornerstone Robotics Limited
E-mail support@csrbtx.com

Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully

– Over 1,000 investment and business matching meetings lined up underscoring Hong Kong’s role as a healthcare investment hub

– ASGH brought together more than 2,900 participants from 42 countries and regions
– Medical Fair attracted some 13,000 buyers from 57 countries and regions
– The two flagship events together resulted in over 390 deal-making sessions and more than 660 business matching meetings
– Collaboration agreements were signed during the events, covering areas including patient care, diagnostic solutions, innovative medical devices, and medical imaging

The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders. ASGH attracted over 2,900 participants from 42 countries and regions, while the Medical Fair received some 13,000 buyers from 57 countries and regions. Over 390 one-on-one deal-making sessions and more than 660 business matching meetings were arranged, facilitating over 1,000 high-quality collaborations and connections. The IHW continues to foster global exchange and cooperation, putting a spotlight on Hong Kong’s vast potential in healthcare investment and trade, and reinforcing its position as a regional leading medical hub.

Dr Peter K N Lam, Chairman of the HKTDC, said: “The Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair concluded with outstanding results driving new collaborations and investments, and injecting new momentum into the healthcare industry. The events brought together leaders across government, business, academia, and investment to tackle today’s healthcare challenges, highlighting Hong Kong’s unique advantages as an international innovation and technology hub under its ‘eight centres’ positioning, actively advancing medical technology, connecting global innovation resources, and paving the way for a healthier and more inclusive future.”

Over 80 industry experts shared insights on healthcare development
The two-day ASGH, jointly organised by the HKSAR Government and the HKTDC under the theme ‘Fostering Global Collaboration for a Shared Future’, focused on a wide spectrum of topics including public health, medical technology breakthroughs, healthy ageing and global business and investment collaboration. The event featured more than 80 speakers comprising government officials and organisations, research pioneers, investors, and business leaders from around the world, all contributing valuable insights to advance global well-being.

Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech during the Plenary Session I: Shaping a More Equitable and Sustainable Health System. Other distinguished speakers, including Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; Martin Taylor, Representative to China, World Health Organization; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; and Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association, shared their insights on tackling global healthcare challenges, offering inspiration for the international healthcare community.

In Plenary Session II: Fostering Global Collaboration for a Shared Future, speakers engaged in a lively discussion on trends in global healthcare collaboration. Among them was Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan, who remarked that more advanced technology and new government regulations are needed to reach a compromise between companies’ profits and patients’ needs.

During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, shared his latest research findings and advanced developments in Alzheimer’s disease.

The summit co-organised sessions under the overarching theme, Shaping the Future of Healthcare, with the Hong Kong University of Science and Technology for the first time. The discussion focused on the potential of AI in healthcare and how innovation could drive breakthroughs in the field. Dr Alex Ng, President of Tencent Healthcare, commented: “One uniqueness of tech companies is that they can be easily distracted by the latest thing. But you do need companies with patience and perseverance to stay in healthcare and make it work.” Prof Graham Cooke, Vice-Dean (Research) Medicine of Imperial College London, also noted that embedding patient needs into healthcare systems is critical, as many innovations fail in translation due to a lack of this focus, with universities playing a key role as innovation drivers.

In Beyond ‘Healthy China 2030’: Driving Health Innovation, speakers explored opportunities in the mainland healthcare market. Marc Horn, Executive Vice President of Merck and President of Merck China, highlighted the two-phase approach of “China for China” followed by “China for the globe”, emphasising healthcare collaboration to develop advanced treatments for global benefit. Dr Zhang Lianshan, Executive Vice President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., stated: “We would like to see our health innovation have realisation of its value, not only in China, but also outside of China. That is why we are talking about Globalisation, where we can achieve maximum value.”

With growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing, Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, and fellow experts explored both the challenges and opportunities posed by ageing populations. Prof Jean Woo highlighted that rapid population ageing is reshaping the global healthcare and socioeconomic landscape. As a city with one of the world’s longest life expectancies, Hong Kong must take early action to strengthen elderly care policies and better allocate health resources. Prof James L. Kirkland also noted that geriatricians ultimately aim to help patients with multiple illnesses reduce medication use while treating their conditions more effectively, enhancing their overall quality of life.

Over 390 deal-making sessions and cooperation agreements open new global opportunities
A key feature of the summit was the ASGH Deal-Making session, which facilitated one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Investment projects spanned pharmaceuticals, medical devices and diagnostics, smart healthcare, and community health and wellness and more than 390 one-on-one meetings were successfully arranged for angel investors, venture capitalists, corporate venture arms, private equity firms and family offices.

The summit facilitated the signing of cooperation agreements, such as those between Gleneagles Hospital Hong Kong and Emerging Viral Diagnostics, and a tripartite collaboration with PanopticAI and SmartCare, HKSH Medical Group and United Imaging Healthcare, China Resources Guangdong Pharmaceuticals and Hong Kong Medtech Association, Hugobiotech and Bridgeway Healthcare Technology, Canossa Hospital and KA Imaging, and others. These agreements covered diverse healthcare areas, including patient care, diagnostic solutions, innovative medical devices, medical imaging and more. Under the tripartite collaboration agreement between Gleneagles Hospital Hong Kong, PanopticAI, and SmartCare, the integration of PanopticAI’s camera-based vital signs monitoring technology and SmartCare’s patient-centered consultation platform will be implemented into Gleneagles clinic in the future.

In addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative technology companies related to the healthcare industry from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand, presenting projects and solutions across key areas such as medical innovation, smart healthcare, AI, big data, telemedicine, and cybersecurity. Zhong Wei, Co-founder of Mitrassist Lifesciences, joined the Shanghai Pavilion and said that ASGH helped them bring non-invasive medical monitoring technologies to Southeast Asia, Africa, and other Belt and Road Initiative countries.

Medical Fair Drives Industry Innovation and Fosters Business Collaboration
The Medical Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, was held alongside ASGH. The Association—formerly known as the Hong Kong Medical and Healthcare Device Industries Association—held a renaming ceremony during the fair, showcasing the deep integration of medical technology and the industry.

The fair brought together some 300 exhibitors from 13 countries and regions, featuring first-time pavilions from the United Kingdom, Thailand and Israel, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. In addition, seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks pavilion, and more than 20 medical enterprises brought by the Hong Kong MedTech Association participated. The Hong Kong Council of Social Service also participated in the fair for the first time. Under the theme Innovations Boosting Smart Health Experience, the exhibition spotlighted three major areas: MedTech, GeronTech and green solutions, with many exhibits featuring applications of AI.

Many exhibitors and buyers successfully expanded their networks and forged new partnerships at the exhibition. Among them was Hong Kong exhibitor Eieling Technology, a company founded to commercialise research outcomes from the Hong Kong Polytechnic University. The firm showcased its non-invasive liver examination technology, which utilises transient elastography technology. Co-founder and CEO Xiaojia Jia noted that only about four companies worldwide possess this technology, making it a major draw for buyers. “During the exhibition, we received intention orders worth several million Hong Kong dollars from mainland China, Hong Kong, Indonesia, and Thailand, involving around ten devices. This is our third year participating, and we’ve observed a significant rise in buyers’ professionalism during our discussions. We look forward to exhibiting again next year.”

Karel Lee, CEO of Neoneco from Korea, sourced innovative medical products at the fair with a minimum budget of USD100,000 and he has already identified RhinoCare, an exhibitor from the Israeli pavilion, for its nasal decongestion device, and is also interested in a medical examination device from a Hong Kong exhibitor. Lee stated, “The exhibition allows us to meet with exhibitors face-to-face, build trust, and accelerate the decision-making process. The HKTDC’s Click2Match platform also facilitated efficient business matching. I have already connected with ten exhibitors, and another twenty reached out to me after learning about my sourcing needs. This is one of Asia’s premium medical sourcing events, and we will definitely return next year.”

Beyond business deals, insightful forums were arranged during the Medical Fair to give inspiration to industry buyers. These included The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area, The MedTech Nexus of the Greater Bay Area, co-organised with the Hong Kong MedTech Association, and Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices, co-organised with the HKCSS. These forums attracted a strong attendance and offered valuable insights into healthcare. Selected sessions are available for replay on the Fair’s website for extended engagement.

This year’s Fair continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing (hktdc.com Sourcing). Click2Match will remain available until 4 June.

Websites
International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en
Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
Hong Kong International Medical and Healthcare Fair:
https://www.hktdc.com/event/hkmedicalfair/en

Photo download: https://bit.ly/4kbr9Nc

Media enquiries
For enquiries, please contact Yuan Tung Financial Relations Limited:

Louise Song	Tel: (852) 3428 5691	Email: lsong@yuantung.com.hk
Tiffany Leung	Tel: (852) 3428 2361	Email: tleung@yuantung.com.hk

HKTDC’s Communications & Public Affairs Department:
Asia Summit on Global Health

Sharon Ha	Tel: (852) 2584 4575	Email: sharon.mt.ha@hktdc.org
Katy Wong	Tel: (852) 2584 4524	Email: katy.ky.wong@hktdc.org
Jane Cheung	Tel: (852) 2584 4137	Email: jane.mh.cheung@hktdc.org

Hong Kong International Medical and Healthcare Fair

Kelly Shek	Tel: (852) 2584 4537	Email: kelly.yt.shek@hktdc.org
Clayton Lauw	Tel: (852) 2584 4472	Email: clayton.y.lauw@hktdc.org

Media Room: http://mediaroom.hktdc.com

About HKTDC
The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.

International Healthcare Week kicks off today

– Asia Summit on Global Health and Medical and Healthcare Fair open concurrently
– Global healthcare leaders gather in Hong Kong to forge new collaboration opportunities

– The Asia Summit on Global Health (ASGH) gathers over 80 government officials and organisations, research pioneers, investors, and business leaders to explore international collaboration on medical technology, silver health, and healthcare systems. A dedicated “Silver Health Chapter” debuts this year to spotlight the ageing population.
– Renowned speakers include Prof John Hardy, the “father of Alzheimer’s disease genetic studies”; Dr Victor Yosef Melt Campos, Chair (2024-2025) of APEC Health Working Group and General Director of International Cooperation at the Ministry of Health of Peru; and Martin Taylor, Representative to China of the World Health Organization. They will share insights on the latest developments in medical innovation.
– The Hong Kong International Medical and Healthcare Fair (Medical Fair) focuses on MedTech, GeronTech, and green solutions, featuring the latest medical health devices, products, and solutions including many AI-powered innovations.
– The Medical Fair has attracted some 300 exhibitors from 13 countries and regions. Participating with pavilions for the first time are Israel, Thailand, and the UK, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg.

International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), officially opened today. One of its flagship events, the fifth Asia Summit on Global Health (ASGH), takes place today and tomorrow (26 and 27 May) at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme Fostering Global Collaboration for a Shared Future, the summit brings together more than 80 healthcare leaders and experts from around the world to explore the future direction of the industry and collaboration opportunities. Another flagship event, the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), also kicks off today (26 to 28 May), and features some 300 exhibitors from 13 countries and regions, showcasing cutting-edge MedTech, GeronTech, and green solutions, including many AI-powered innovations, to foster global industry collaboration.

The ASGH opened with welcome remarks delivered by HKTDC Chairman Dr Peter K N Lam. “The global health sector is currently facing challenges, including a resurgence in infectious diseases, coupled with the growing needs of an ageing population and ongoing health equity concerns. These issues demand urgent attention and collective action to protect communities worldwide. Now in its fifth edition, ASGH is a key event for the global healthcare industry, and we are proud that connections made through ASGH have enabled many new investments and collaborations in healthcare innovation. Alongside ASGH, the Hong Kong International Medical and Healthcare Fair is taking place. There, you will find the latest HealthTech solutions from around the globe, with a particular focus on hospital equipment, rehabilitation, elderly care and biotech. As anchor events of the International Healthcare Week, ASGH and Medical Fair highlights Hong Kong’s commitment to working with partners to nurture an innovative health and medical sector,” Dr Lam said.

In his opening speech, Hong Kong SAR Chief Executive John Lee said: “Under the theme of “Fostering Global Collaboration for a Shared Future”, this summit reaffirms Hong Kong’s pivotal role as a leading health innovation hub in the region. Under the “one country, two systems” principle, Hong Kong enjoys unique connectivity with both Mainland China and the world. As the world’s freest economy and one of the top three international financial centres, we offer an efficient, open and fair business environment with robust intellectual property protection. We maintain free flows of information, capital, goods and talent. We are also emerging as a leading hub for scientific innovation, technological advancement and world-class education.”

Prof Cao Xuetao, Vice-Minister of the National Health Commission of the People’s Republic of China, gave special remarks, noting: “China continues to open up and welcomes leading foreign-owned hospitals into the market through investment or joint ventures. We hope that our global partners can further localise and upgrade their mid-to-high-end products, resulting in win-win outcomes for all.”

Additionally, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), delivered remarks at the opening session via video link and stated, “The theme of ASGH could not be more appropriate given the challenges facing global health at the moment. The WHO Pandemic Agreement has been adopted recently. It was negotiated over the past three and a half years and shows a true spirit of international collaboration for global health. By working together, we can build a healthier, safer, and fairer world for all.”

Global industry leaders gather to explore opportunities for international collaboration
Today’s Plenary Session I: Shaping a More Equitable and Sustainable Health System, featured keynote remarks by Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, and Feng Haicang, Level I Bureau Rank Official of Department of Consumer Goods Industry, Ministry of Industry and Information Technology of the People’s Republic of China.

Prof Lo Chung-mau, stated: “A sustainable health system requires talents and enough healthcare manpower. While the Government has been addressing the issue of manpower shortage through a multipronged strategy, by increasing the number of intakes for local universities and admitting qualified non-locally trained healthcare workers, the 2024 Policy Address announced that the Government supports the plan to establish a third medical school. Indeed, Hong Kong has already hosted two top 30 world class medical schools but we have the ability and the need to develop the third one which shall adopt an innovative strategic positioning in pursuit of complementary development with the two existing ones.”

The session was moderated by Prof Tsui Lap-chee, Chairman of the University of Hong Kong Foundation for Educational Development and Research, focused on key issues faced by healthcare systems in addressing global challenges. Distinguished speakers included Martin Taylor, Representative to China of the WHO; and Prof Nancy Ip, President of the Hong Kong University of Science and Technology. They shared valuable experiences and forward-looking insights to inspire the global healthcare field.

Prof Nancy Ip noted: “Universities are more than academic institutions. They are global connectors, neutral platforms, and also engines of innovation, uniquely positioned to bridge divides between disciplines, industries, and also nations.”

Distinguished international speakers of Plenary Session II: Fostering Global Collaboration for a Shared Future included Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan. They jointly explored trends in global healthcare collaboration, injecting new ideas into constructing a more synergistic global healthcare landscape.

The summit invited Prof John Hardy, known as the “father of Alzheimer’s disease genetic studies”, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, to share his outlook on future research and treatment of neurodegenerative diseases such as Alzheimer’s in the Dialogue with Global Pioneer in Health session.

Prof John Hardy remarked: “For Alzheimer’s treatment, I think that two changes can happen quite quickly: improvements in earlier diagnosis, and development of drugs that bypass the blood vessel-based amyloid. What we want to do with drugs is slow decline. If we understand what underpins that decline, it gives us targets, and we’re very excited by some of the findings in that area now.”

“Healthy China 2030” serves as the national blueprint for healthcare policy development in Mainland China. In the session Beyond “Healthy China 2030”: Driving Health Innovation, Dr Zhang Lianshan, Executive Vice President, Jiangsu Hengrui Pharmaceuticals Co., Ltd.; and Marc Horn, Executive Vice President of Merck and President of Merck China, explored opportunities in the mainland healthcare market, analysing emerging trends in China’s healthcare innovation ecosystem to open new pathways for international collaboration with other speakers.

Diverse topics converge with forward-looking insights and the Silver Health Chapter explores new business opportunities
For the first time, the summit co-organised two thematic sessions with the Hong Kong University of Science and Technology under the overarching theme Shaping the Future of Healthcare. Speakers included Prof Graham Cooke, Vice-Dean (Research) of Faculty of Medicine at Imperial College London. They focused on the potential of AI in the medical field, sharing with participants how innovative technologies are driving new breakthroughs in healthcare. Additionally, sessions on Peeking into the Future of Gene and Cell Therapies and Women’s Health in Focus were also closely aligned with global medical development trends.

Continuing today’s in-depth dialogues, more exciting sessions will be presented tomorrow. For the first time, the summit will feature a Silver Health Chapter focusing on addressing the challenging ageing societies. Speakers including Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, will gather at tomorrow morning’s session Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology to delve into how to address the challenges brought by an ageing population, analysing future development trends and potential investment opportunities in the silver economy market.

Furthermore, globally renowned speakers will be present tomorrow to share their valuable experiences and insights. Wyman Li, Chief Operating Officer of HKSH Medical Group; Prof Karim Asehnoune, President of National Committee for Public Hospital Research (CNCR), and other speakers will analyse how to promote the sustainable development of the healthcare industry through collaboration among different stakeholders in the session, Reinventing the Business of Healthcare through Partnerships. Prof Xu Hongxi, Distinguished Professor and Honorary Dean of Shanghai University of Traditional Chinese Medicine and other guests will discuss the latest developments and commercial potential of integrating Chinese and Western medicine in the session The Convergence of Chinese and Western Medicine in Global Health. Sessions on The Next Wave of Innovations in Neuroscience, Data-driven Healthcare Transforming Patient Journey and The Changing Face of Cancer will also be held tomorrow.

A global platform for healthcare resource matchmaking to foster opportunities for innovative collaboration
In addition to thematic discussions, the summit also aims to bridge global collaboration among participants. For example, the ASGH Deal-making facilitates one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations.

The summit has established the ASGH Business Hub, which brings together more than 170 innovative technology companies and award-winning projects from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand. The InnoHealth Showcase serves as a platform to explore business opportunities and innovative solutions and highlights more than 70 healthcare start-ups and projects led by the Innovation and Technology Commission, Cyberport, and six local universities. The showcase is structured around four key categories: pharmaceuticals and therapeutics, AI and Digital Health, medical devices and diagnostics, and community health and wellness. As part of the “Silver Health Chapter”, some of the showcased projects address the challenges of an ageing population, including early blood tests for Alzheimer’s disease, demonstrating cutting-edge capabilities and market potential in elderly healthcare.

Integrating global innovations to showcase the future of healthcare
The Hong Kong International Medical and Healthcare Fair also opened today, organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA). Under the theme Innovations Boosting Smart Health Experience, this year’s Fair focuses on three key areas: MedTech, GeronTech and green solutions, featuring the latest medical health devices, products, and solutions.

In the field of MedTech, UK exhibitor London Medical Exchange (Booth No: 3F-H15) presents a fully automated AI-powered patient monitoring system designed to improve patient care, transforming healthcare from reactive to proactive. Meanwhile, C2iTech (Booth No: 3F-G04), established by a research team from the School of Public Health at The University of Hong Kong, showcases a Respiratory Organoid Platform (ROP). By analysing nasopharyngeal or throat saliva samples from individuals, the platform predicts their likely response to respiratory virus infections, enabling more precise and personalised treatment by healthcare professionals.

In the GeronTech segment, Medmind Technology (Booth No: 3F-G04), from the Hong Kong Science and Technology Parks Corporation (HKSTP) Pavilion, introduces an app for cognitive impairment assessment. The tool allows middle-aged and elderly users to play digital mahjong and other games, with AI used to assess their cognitive status and offer personalised brain training, helping prevent and detect early signs of cognitive decline. The system can also monitor patient conditions over time.

The Hong Kong Council of Social Service (HKCSS), participating in the fair for the first time, is showcasing a range of GeronTech and related products, covering areas such as rehabilitation and mobility assistance, cognitive impairment support for patients and carers, and smart home solutions. HKCSS is also introducing its GeronTech education and rental services, along with its online platform that enables the public to learn about and hire GeronTech equipment. Users such as the elderly, people in rehabilitation, and carers can try out products, and rent or purchase them as needed, with support from a cross-disciplinary professional team. Through the Medical Fair, HKCSS aims to attract collaboration with other businesses to expand its services and benefit a wider segment of the community.

For green solutions, MassPhoton (Booth No: 3F-H18), also from the HKSTP Pavilion, presents an ultraviolet disinfection system that combines semiconductor and smart control technologies, delivering more efficient and energy-saving disinfection for air, water and surfaces.

This year’s Medical Fair has attracted some 300 exhibitors from 13 countries and regions. Participating with pavilions for the first time are Israel, Thailand, and the UK, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. Highlighting Hong Kong’s strength in medical innovation, seven local universities, over 30 innovative technology companies at the HKSTP pavilion, and more than 20 medical enterprises brought by the HKMHDIA are participating.

The exhibition features a range of thematic zones, including Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Products, and Start-up and HKMHDIA zones. Highlight exhibits include AI-powered rehabilitation systems, portable ultrasound diagnostic systems, and smart hospital robots, demonstrating the frontiers of medical and healthcare technology.

During the Medical Fair, there will be forums, seminars and networking receptions. Two forums focused on the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) healthcare sector will take place tomorrow. The morning forum titled The MedTech Nexus of the Greater Bay Area, which is co-organised with the HKMHDIA, will feature industry experts sharing insights on intellectual property strategies for biomedical innovation, ways to integrate resources for GBA market development, and successful experiences in promoting medical technology in the GBA. The afternoon forum titled The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area will bring together experts from the Greater Bay Area Centre for Medical Device Evaluation and Inspection of National Medical Products Administration, the Medical Device Division of Department of Health, and SGS-CSTC Standards Technical Services Co., Ltd., to explore the latest developments, administrative systems and regulations in relevant fields, promoting cross-regional regulatory collaboration and fostering innovation through idea exchange.

Using the HKTDC EXHIBITION+ hybrid model, global exhibitors, industry professionals, and buyers can continue business matching via the Click2Match smart business matching platform until 4 June, encouraging more cooperation.

Aside from ASGH and the Medical Fair, IHW also features the Hospital Authority Convention, among many other industry events.

Photo download: https://bit.ly/43xCK2b

Websites
International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en

Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme
Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker

Hong Kong International Medical and Healthcare Fair:
https://www.hktdc.com/event/hkmedicalfair/en
List of products: https://www.hktdc.com/event/hkmedicalfair/en/product
Activity schedule: https://www.hktdc.com/event/hkmedicalfair/en/intelligence-hub

Media enquiries
For enquiries, please contact Yuan Tung Financial Relations Limited:

Louise Song	Tel: (852) 3428 5691	Email: lsong@yuantung.com.hk
Tiffany Leung	Tel: (852) 3428 2361	Email: tleung@yuantung.com.hk

HKTDC’s Communications & Public Affairs Department:
Asia Summit on Global Health

Sharon Ha	Tel: (852) 2584 4575	Email: sharon.mt.ha@hktdc.org
Katy Wong	Tel: (852) 2584 4524	Email: katy.ky.wong@hktdc.org
Jane Cheung	Tel: (852) 2584 4137	Email: jane.mh.cheung@hktdc.org

Hong Kong International Medical and Healthcare Fair

Kelly Shek	Tel: (852) 2584 4537	Email: kelly.yt.shek@hktdc.org
Clayton Lauw	Tel: (852) 2584 4472	Email: clayton.y.lauw@hktdc.org

Media Room: http://mediaroom.hktdc.com